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The Wilms’ tumor suppressor WT1: Approaches to gene function.
Occurring with a frequency of 1 in 10,000 live births, Wilms’ tumor is one
of the most common solid tumors of children. The genetic basis of this
tumor is highly complex and several loci have been shown to be associated
with tumor formation. Thus far, however, WT1 is the only gene that has
been isolated and proven to carry mutations within Wilms’ tumors. During
the last few years, a wealth of experiments has been carried out to address
the function of WT1 as a tumor suppressor and developmental regulator.
This review focuses on studies addressing WT1 function; new approaches
to understand WT1 function in vivo and present transgenic data in which
WT1 was driven ectopically using a CMV promoter are discussed. Our
results suggest that ubiquitous expression of WT1 is not compatible with
embryonic development.
Normal development is the result of tightly controlled prolifer-
ation, differentiation and apoptosis of cells. Deregulation of any
of these processes may lead to abnormal development. Wilms’
tumor is a clear example of disrupted development. In early
kidney development, the ureteric bud invades the pluripotent
mesenchymal cells, located in the cortical regions. Upon induction
by the ureteric bud, the proliferating mesenchymal cells differen-
tiate into stromal cells or condense and form via the comma- and
S-shaped bodies the nephrons. Three percent of the cells within
the nephrogenic areas are apoptotic at any given time, implying
that large-scale apoptosis also takes place [1]. Wilms’ tumor is
derived from metanephric blastemal tissue of the developing
kidney that has failed to undergo the normal maturation process.
It therefore represents an excellent model to study the links
between cancer and development.
THE WILMS’ TUMOR GENE WT1
Although cytogenetic and molecular studies indicate that sev-
eral chromosomal regions may be involved in the development of
Wilms’ tumor, so far only one gene has been cloned and proven to
play a role in the etiology of this type of tumor: the Wilms’ tumor
1 gene. Cloning of WT1 was mainly guided by heterozygous
deletions on human chromosome 11p13, which are associated
with the congenital WAGR syndrome (Fig. 1A). This syndrome is
characterized by a variety of developmental abnormalities includ-
ing aniridia, genital anomalies, mental retardation and a high risk
of developing Wilms’ tumor. To date, three genes have been
identified within the WAGR region: the paired box gene PAX6
[2], the calcium binding protein reticulocalbin [3] and the zinc
finger gene WT1 [4]. WT1 mutations are found in about 20% of
Wilms’ tumors, implying that the gene may play an important role
in the formation of Wilms’ tumor and genital abnormalities in the
WAGR patients. Mutations within the WT1 locus are also found
in Denys-Drash patients. These patients show diffuse mesangial
sclerosis combined with genital abnormalities and a high risk of
developing tumors. In contrast, to other WT1 mutations, these
mutations are dominant and mainly found in the zinc finger region
of WT1 (see below).
The organization of the WT1 locus is quite complex. The gene
contains ten exons, covering approximately 50 kb (Fig. 1B) [4–7].
As a result of alternative RNA splicing [5], the gene encodes four
different proteins with molecular weights of 52 to 54 kDa [8]. One
alternative splicing event results in either inclusion or exclusion of
exon 5, which encodes a stretch of 17 amino acids (617aa) just
N-terminal of the four zinc fingers. The other alternative splicing
event involves a splice acceptor site in exon 9, resulting in the
presence or absence of a three amino acid insert [lysine-threo-
nine-serine (6 KTS)] between zinc fingers three and four. For the
purpose of this review, we will refer to the WT1 splice variant that
lacks both inserts as the WT1(2/2) isoform, the splice variant
which only contains the 17aa insert as the WT1(1/2) isoform, the
splice variant that only contains the KTS insert as the WT1(2/1)
isoform, and the splice variant that contains both inserts as the
WT1(1/1) isoform. Recently, a second translational initiation
site has been identified resulting in WT1 proteins with a higher
molecular weight [9, 10]. Together with the observed RNA editing
[11], there may be as many as 16 different WT1 isoforms (Fig. 2).
What is the function of all these variants? Do they serve different
functions and are they all required for normal development? In
the following review we will try to summarize the large number of
experiments carried out in vitro and suggest new approaches to
address WT1 function in vivo.
FUNCTIONAL ANALYSIS OF THE WT1 PROTEIN IN
TISSUE CULTURE SYSTEMS
Transient expression systems
The predicted protein sequence provided a first clue for the
biochemical function of WT1 [4]. It features four zinc fingers of
the Kruppel C2-H2 class in the carboxyl-terminal part and a
proline-glutamine-rich amino terminus, suggesting a role of WT1
as a transcription factor.
To elucidate potential target genes for WT1 initial studies
focused on binding site selection with oligonucleotides, whole
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genomic PCR and DNAse I footprint analysis [12–15]. Extrapo-
lation of these data suggested a consensus motif for WT1 DNA
binding, and comparison with known promoter sequences led to
the identification of a number of putative WT1-target genes
(Table 1).
To confirm these candidate targets, transient transfection as-
says were performed. In these experiments, WT1 expression
vectors were cotransfected into cells with a reporter gene driven
by the promoter to be tested. The results indicated that WT1
could affect the promoter activity of all of the tested candidates
(Table 1), but also showed that the different WT1 isoforms have
distinct transactivation activities [12, 16, 17]. Initially, it was found
that only splice variants lacking the KTS insertion could repress
the transcription of reporter constructs containing Egr-1-like
consensus sequences in their promoter region [12, 16]. This
suggested that WT1(1KTS) and the WT1(2KTS) isoforms reg-
ulate different target genes. However, later studies showed that
both the WT1(1KTS) and the WT1(2KTS) proteins could bind
overlapping DNA sequences in the promoters of the IGF II gene
[18], the gene for the platelet-derived growth factor (PDGF)-A
chain [19], the Wilms’ tumor 1 gene [20], and the PAX-2 gene
[21]. The presence or absence of the 17aa stretch does not seem
to affect the DNA binding activity. Instead, this insert seems to
have a suppressor function in addition to more N-terminally
located sequences [16, 19, 22]. The WT1(1/1) protein suppresses
the activity of the WT1 promoter about 25-fold better than the
WT1(2/1) protein in transient transfection assays [20]. It has
even been observed that the WT1(1/1) protein represses tran-
scription of a certain modified PDGF-A promoter construct,
whereas the WT1(2/1) protein activates transcription [19]. Al-
though the transient transfection assays are very informative
concerning the potential transcriptional activity of the WT1 splice
variants, conclusions have to be drawn with care. The choice of
the cell system, the type of expression vector or the exact topology
Fig. 1. Schematic drawing of the WAGR region on human chromosome 11p13. Abbreviations are: Tel, telomere; CeN, centromere. The open box
represents deletions associated with the WAGR syndrome. YAC WT470 (same as yIE5, Fantes et al) is indicated by a double arrow below the
chromosome (RCN 5 reticulocalbin gene). (B) Illustration of the human WT1 locus. Exons are indicated by filled boxes. Several l clones isolated during
this study are indicated below the chromosomal line. (C) Schematic drawing of the homologous recombination approach chosen to truncate WT470.
The end fragment of lWT11 was cloned into an amplifiable retrofitting vector. After homologous recombination with YAC WT470 a 280 kb construct
was recovered. (D) PFGE analyses of YAC constructs. Amplification of the two YACs (WT470 ampl. and WT280 ampl.) leads to an increase of copy
numbers compared to the endogenous yeast chromosomes (WT470). This allows the isolation of pure and highly concentrated YAC DNA for injection
(WT470 isol., WT280 isol.).
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of the reporter construct have been shown to influence the activity
of the WT1 proteins as transcriptional regulators [19, 23–25], thus
questioning the physiological significance of some of the findings.
More recent studies suggest a completely different role for at
least some of the WT1 isoforms. Nuclear staining of COS cells,
transiently transfected with each of the four WT1 splice variants,
showed that the WT1(1KTS) proteins localize to the nucleus in a
more “speckled” pattern compared to the “diffuse” pattern of the
WT1(2KTS) isoforms [26]. A detailed comparison of staining
patterns obtained with antibodies against WT1 and splicing
factors showed that WT1(1KTS) proteins colocalize and associ-
ate with proteins of the splicing machinery. These findings sug-
gested a role for WT1(1KTS) isoforms in splicing. In support of
such a function, an evolutionary conserved N-terminal RNA
recognition motif (RRM) has recently been identified in all
known WT1 isoforms (Fig. 2) [27]. However, in another study the
WT1(1KTS) isoforms do not colocalize with SC35, a spliceosome
assembly factor that is required for the initial step of pre-mRNA
splicing [28]. Further studies, in particular addressing potential
RNA targets, are needed to clarify the role of WT1 in posttran-
scriptional regulation and splicing.
Stable expression
One of the drawbacks of transient transfection studies is the
production of large amounts of protein within the transfected cell,
which often exceed physiological levels by several orders of
magnitude. In order to get more physiological levels of the WT1
proteins, stable transfections have been performed in which the
construct integrates in the host genome.
We have made stable transfectants expressing the WT1(1/1),
the WT1(2/1), the WT1(1/2) or the WT1(2/2) splice variants
[29]. Interestingly, expression of the WT1(2/2) isoform increased
the tumorigenicity of adenovirus transformed baby rat kidney cells
whereas expression of the WT1(2/1) suppressed the tumor
growth. However, as with the transient transfection assays, the
effects of the WT1-isoforms appear to be cell type dependent. The
WT1(2/2) isoform for example, suppresses the tumorigenicity of
NIH3T3 cells [30], has no effect when expressed in 7C1T1 cells
(Note added in proof), but increases the tumor growth rate in
7C3H2-Ad-BRK cells [31].
Fig. 2. Structure of the WT1 protein. Four
zinc fingers are located in the C-terminus of
the protein. Potentially 16 different isoforms
can be created from the WT1 locus. The grey
boxes above the protein represent two
alternatively spliced exons. RNA editing at
position 839 leads to the replacement of a
uracil by cytosine (change from Leu to Pro in
the amino acid sequence). An alternative
translation start-site 204 basepairs upstream
of the major ATG creates isoforms with an
additional 68 amino acids. The position of
structural motifs and protein domains is
indicated below the illustration.
Table 1. Candidate target genes for the WT1 protein
Gene Reference Author Date
Wilms’ tumor 1 [43] Hoffmann et al (1993)
[20] Rupprecht et al (1994)
[44] Malik et al (1994)
[45] Hewitt et al (1996)
Egr-1 [16] Madden et al (1991)
[12] Rauscher et al (1990)
[25] Reddy et al (1995)
IGF-II [18] Drummond et al (1992)
[46] Nichols et al (1995)
IGF-I receptor [47,48] Werner et al (1993, 1994)
PDGF-A [49–51] Wang et al (1992, 1993, 1995)
[52] Gashler et al (1992)
CSF-1 [52] Harrington et al (1993)
TGF-b [54] Dey et al (1994)
PAX-2 [21] Ryan et al (1995)
Nov-H [55] Martinerie et al (1996)
RAR-a [56] Goodyer et al (1995)
Inhibin-a [57] Hsu et al (1995)
C-myb [58] McCann et al (1995)
ODC [59] Moshier et al (1996)
G-protein ai-2 [60] Kinane et al (1996)
Bcl-2 [61] Hewitt et al (1995)
C-myc [61] Hewitt et al (1995)
[15] Wang et al (1993)
EGF receptor [24] Englert et al (1995)
[15] Wang et al (1993)
Ki-ras [15] Wang et al (1993)
Insulin receptor [15] Wang et al (1993)
Syndecan-1 [62] Cook et al (1996)
Midkine [63] Adachi et al (1996)
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Inducible expression
In several cases it has been very difficult to stably express WT1.
This can be explained by the potential of WT1 to induce apoptosis
in certain cell types [24, 31]. The induction of apoptosis may well
be a legitimate function of WT1 (Note added in proof). To
overcome this problem, Englert et al [24] created cell lines in
which WT1 expression could be induced. Upon induction of WT1
expression in U2OS cells, the expression of the EGF-receptor was
down-regulated and the cells underwent apoptosis. In addition,
overexpression of the EGF-receptor rescues both U2OS [24] and
Hep3B cells [31] from WT1-induced apoptosis, making this
receptor a potential target gene of WT1. The physiological
significance, however, of these results remains to be elucidated. In
contrast to the previous results, treatment of the WT1 expressing
leukemia cell line K562 with antisense WT1 stops the growth of
these cells, which subsequently undergo apoptosis [32].
From transient transfection experiments, tumorigenicity test
and apoptosis assays we know that each of the WT1 splice variants
may have a different function. The ratio between the splice
variants may therefore be important in determining the overall
effect of WT1 expression. It is also clear that a lot of the functions
ascribed to the WT1 proteins are cell-type dependent. Some of
the contradictory results may be explained by the absence or
presence of modifier proteins like P53 [23], par-4 [33] and UBC9
[34]. Thus far, only these modifiers have been identified, but there
may be many more. To what extent WT1 expression will have an
effect may in addition be determined by the cross-talk between
the cell and its cellular environment. Overexpression of WT1 in
F9 embryonic carcinoma cells, for example, only induces apopto-
tic cell death in the presence of retinoic acid [35].
Functional analysis of the WT1 protein in vivo
From the cell culture data we can conclude that the function of
the WT1 gene in vivo will be affected by the cell-type in which it
is expressed, the ratio of the splice variants being expressed and
the cellular environment. Because of these findings it becomes
clear that the only way of gaining additional insights into WT1
function is an analysis in an in vivo situation. Certainly one
important step into the right direction was the generation of
knock-out mice [36]. A WT1 null mutation in these mice results in
failure of kidney, gonad and mesothelium development. The
blastema cells fail to differentiate and undergo apoptosis and the
embryo becomes edematous after 12 days of development and is
resorbed. However, the early lethality excludes the analysis of the
function of WT1 at later stages. In the adult, for example, WT1
continues to be expressed in the podocytes, the sertoli cells, the
mesothelium cells and the granulosa cells.
In a first attempt to address gene function in vivo we wanted to
ubiquitously express the gene. Such an approach, we hoped,
would result in abnormal development of tissues that are compe-
tent to react to WT1 function. The WT1 splice variants are
conserved in all mammals tested [37]. Also, at the gross tissue
level it seems that the ratio between the WT1 isoforms remains
constant throughout development and in different mammals [6,
38, 39], suggesting that the combined expression of all splice
variants may be essential for normal functioning. In order to get
expression of all splice variants, we chose to make transgenic mice
with YAC DNA containing the whole genomic sequence of WT1.
A 470 kb YAC covering the human locus has been described
before [40]. To allow an easier manipulation of the construct we
first truncated the YAC using a homologous recombination
approach. To do this a l sublibrary was constructed and a
fragment located 10 kb downstream of the WT1 gene was cloned
into a fragmentation vector. Truncation of WT470 was achieved
by homologous recombination in yeast, which resulted in a 280 kb
YAC construct (Fig. 1C, D). In the next step we introduced the
CMV promoter about 28 bp upstream of the major WT1 trans-
lation start site (details on request). Targeting in yeast resulted in
the expected hybridization pattern (Fig. 3). Before starting injec-
tions the modified YAC, CMV-WT280, was checked carefully for
the absence of rearrangements.
Initially we injected 341 fertilized oocytes and transferred them
to pseudo-pregnant foster mothers. None of the 47 survivors
carried the transgene. This made us believe that the transgenic
construct may cause lethality in mice and we started to recover the
transferred embryos on days 9.5 to 14.5 of development. Extensive
injection experiments were carried out with a total of 1228
injected oocytes transferred to foster mothers. Embryonic sacs
were isolated and checked for the presence of the YAC using
PCR. Only one embryo out of 293 showed a faint signal by PCR
but not by Southern blotting, suggesting that the animal was
mosaic for the transgene. To ensure that the experimental system
of YAC transgenesis was working properly, in parallel we injected
WT280, the same construct, but lacking the CMV promoter. In
these experiments a high percentage (5%) of newborn offspring
carried the transgene (Table 2). Taken together, our data indicate
that the CMV YAC is incompatible with normal development. As
the only difference between WT280 and CMV-WT280 is the
inserted CMV promoter (the Leu2 gene has no effect in similar
experiments with other transgenic constructs; A. Schedl, unpub-
lished results) we can conclude that ubiquitous expression of WT1
is causing embryonic lethality.
NEW APPROACHES TO WT1 FUNCTION
Extrapolation of the cell culture data to the in vivo situation
predicts that spatial or temporal expression failures, or changes in
the ratio between the WT1-isoforms may have devastating effects.
A cell may undergo apoptosis while it should differentiate or
proliferate. The CMV-promoter drives the expression of the WT1
gene in any tissue, which may be fatal early in development. To
circumvent this problem one could make use of different tissue
specific promoters. The development of transgenic mice that
ectopically express WT1 may help to prove certain hypotheses like
the involvement of WT1 in muscle development and the transition
of mesenchymal cells to epithelial cells [41].
Not only the localization but also the timing of the expression
will be important. In the kidney, for example, the expression
pattern of the WT1 gene suggests that WT1 may function at three
different stages of development: the onset of nephrogenesis, the
progression of nephrogenesis and the maintenance of normal
podocyte function. Absence of WT1 at the first stage results in
failure of kidney development as has been observed in WT1 null
mice [36]. The blastema cells fail to differentiate and undergo
apoptosis. What will happen if the expression of WT1 is switched
off later in development? Will these cells proliferate instead and
form a tumor? To address these questions we may make use of the
recently described doxycycline-mediated quantitative and tissue-
specific control of gene expression in transgenic mice [42]. With
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this system it would be possible to switch the WT1 gene on or off
at different stages of development by adding doxycycline to the
drinking water of the mice. In the same way we could use this
system to disrupt the ratio between the splice variants at different
stages of development by boosting the expression of just one
isoform.
Finally, the introduction of specific point mutations into the
mouse germline will allow alternatively spliced isoforms of WT1
to be specifically knocked out, and thus address their individual
functions in vivo.
SUMMARY AND OUTLOOK
The WT1 gene has been implicated in many processes like
proliferation, differentiation and apoptosis. In agreement with
these diverse functions is the growing list of putative target genes.
Many of these may be identified as real target genes in vivo. At the
moment one can only speculate about the function of WT1.
Expression of the gene may allow a cell to respond appropriately
to signals from its environment and the many isoforms may aid in
fine tuning this response. For example, during embryonic devel-
opment, WT1 expression may render the metanephric mesenchy-
mal cells susceptible to induction by the ureteric bud. In the adult,
in a similar way, WT1 may render the sertoli cells, the granulosa
cells and the decidual cells susceptible to induction by the germ
cells. Further development of mouse models will be important to
help to clarify these possible interactions.
Reprint requests to Dr. Andreas Schedl, MDC for Molecular Medicine,
Robert-Ro¨ssle-Str.10, 13122 Berlin-Buch, Germany.
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